Read a refresh of GI cancer FDA news from August 2026, including the approval of a RAS(ON) inhibitor in metastatic pancreatic cancer.
News|Videos|May 26, 2026
Cemiplimab monotherapy for first-line advanced NSCLC patients with PD-L1 expression ≥50%: 6-y outcomes of EMPOWER-Lung 1
Author(s)Chul Kim, MD, MPH
Fact checked by: Judy Schreiber, PhD, RN
Rapid readout: Real-world lifileucel TIL shows 44% responses in metastatic melanoma, favoring early referral and manageable IL-2 toxicity.
Advertisement
Updated findings from the phase 3 EMPOWER-Lung 1 trial showed that first-line cemiplimab monotherapy continued to provide durable survival benefits compared with chemotherapy in patients with advanced NSCLC and high PD-L1 expression.
Advertisement
Related to this article
The FDA has approved belzutifan (Welireg) plus lenvatinib (Lenvima) for use in patients with advanced renal cell carcinoma with a clear cell component after PD-1 or PD-L1 inhibition.
R. Lor Randall, MD, FACS, discusses AI in musculoskeletal tumor diagnosis, surgical planning and robotics, and validation of AI tools.
MAPK drugs restore TSHR in aggressive thyroid tumors, helping CAR-T cell therapy see and control solid tumors again.
An FDA advisory committee voted in favor of the benefits of the Galleri MCED test outweighing its risks in patients 50 years of age and older.
Novel approaches to the use of AI in oncology may require discussion and ultimately modification of existing proprietary and regulatory barriers.
Extended follow-up from the phase 1b CAMMA 1 trial showed durable responses across two cevostamab dose levels, supporting selection of a recommended phase 3 regimen.
A MAIC found anito-cel produced response rates similar to those of cilta-cel, with fewer high-grade toxicities, in relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Belzutifan Plus Lenvatinib for Advanced ccRCC
2
AI Enables Enhanced Decision Making and New Opportunities in Orthopedic Oncology
3
Breaking Down the FDA Approval of Zanidatamab-Based Regimens in HER2+ Gastric Cancer
4
Dr Encinas Mayoral on an AI-Designed BCMA/FcRL5-Targeting TRiTE in Multiple Myeloma
5